Innovations for screening and prognosis in HIV+ cancers including Kaposi sarcoma, cervical cancer, and lymphoma in Malawi and South Africa

马拉维和南非的艾滋病毒癌症筛查和预后创新，包括卡波西肉瘤、宫颈癌和淋巴瘤

• 批准号: 10238155
• 负责人: Carla J Chibwesha
• 金额: $ 110.9万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-08-13 至 2025-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10238155
• 关键词: AIDS Malignancy Consortium; AIDS clinical trial group; AIDS related cancer; AIDS-Related Lymphoma; AIDS/HIV problem; Achievement; Acquired Immunodeficiency Syndrome; Address; Africa; Africa South of the Sahara; Basic Science; Biological Markers; Cancer Burden; Cancer Control; Cancer Prognosis; Caring; Clinical Research; Clinical Sciences; Clinical Trials; Collaborations; Communicable Diseases; Communities; Comprehensive Cancer Center; Crystallization; Data; Ensure; Epidemic; Flowers; Goals; HIV; Health; Hospitals; Individual; Infrastructure; Institutes; Institution; International; Kaposi Sarcoma; Knowledge; Leadership; Lymphoma; Malawi; Malignant Neoplasms; Malignant neoplasm of cervix uteri; Medicine; Methods; Molecular; North Carolina; Patients; Persons; Policies; Population Sciences; Positioning Attribute; Principal Investigator; Prognosis; Recurrence; Research; Research Infrastructure; Research Personnel; Research Priority; Research Project Grants; Science; Site; South Africa; South African; Survival Rate; Training; Training Support; Training and Infrastructure; Translational Research; Trust; UNC Lineberger Comprehensive Cancer Center; United States National Institutes of Health; Universities; anticancer research; antiretroviral therapy; career; clinical research site; college; combat; comorbidity; data sharing; epidemiology study; global health; high risk; improved; innovation; insight; low and middle-income countries; next generation; oncology program; programs; response; screening; success; translational impact; tumor

ABSTRACT: OVERALL COMPONENT: Innovations for screening and prognosis in HIV+ cancers including Kaposi sarcoma, cervical cancer, and lymphoma in Malawi and South Africa In response to RFA-CA-20-001, this application proposes to establish the UNC-Malawi-South Africa Cancer Consortium (UMSACC), to develop capacity and conduct high-impact research focused on HIV-associated cancers. The consortium builds on longstanding collaborations between the University of North Carolina at Chapel Hill, Lighthouse Trust in Malawi, Malawi Ministry of Health, Malawi College of Medicine, the University of the Witwatersrand, South Africa, and Stellenbosch University, South Africa. These partnerships have been made possible by leadership and participation in NIH networks conducting basic, clinical and epidemiologic research in the region. These existing relationships and robust infrastructure can now be leveraged for HIV- associated malignancies, which are overwhelming contributors to cancer burden in Malawi and South Africa even after widespread antiretroviral therapy usage. UMSACC is focused on the three most common HIV- associated cancers, Kaposi sarcoma (KS), cervical cancer, and lymphoma, and addresses the NIH HIV/AIDS research priorities by focusing on HIV-associated comorbidities which includes these AIDS-defining cancers. UMSACC proposes innovations for screening and prognosis of these cancers in persons living with HIV (PLWH) with the overall goal being to improve the health of PLWH. Our consortium will be led by principal investigators with highly complementary expertise using a team science approach. To support consortium objectives, a diverse team of investigators has been assembled spanning the clinical, population, and basic sciences, and includes Malawian, South African, and US scientific leaders. Moreover, a high priority is the training and support of junior investigators in the U.S. and Africa. The consortium will enhance existing administrative, operational, and research relationships between all partnering institutions and investigators. The External Advisory Board and Scientific Advisors will ensure that the consortium remains highly responsive to community needs in Malawi and South Africa, while also addressing urgent research questions facing the international HIV-associated cancer community. A focus of this consortium is to develop Malawi and South Africa to become international leaders in HIV- associated cancer research. Building on prior successes and partnerships outlined in this application, UMSACC is extremely well-positioned to catalyze a broad, coordinated, cancer control effort in Malawi and South Africa, and to advance the overall NCI scientific agenda for sub-Saharan Africa to reduce HIV- associated cancer burden in low- and middle-income countries.

摘要：总体组成部分：HIV+癌症筛查和预后的创新 包括马拉维和南非的卡波西肉瘤、宫颈癌和淋巴瘤 作为对RFA-CA-20 - 001的回应，本申请建议建立UNC-马拉维-南非癌症中心 联合会（USSACC），以发展能力和开展高影响力的研究，重点是与艾滋病毒有关的 癌的该联盟建立在北卡罗来纳州大学与 查佩尔山、马拉维灯塔信托基金、马拉维卫生部、马拉维医学院、大学 南非威特沃特斯兰德大学和南非斯泰伦博斯大学。这些伙伴关系一直是 通过领导和参与国家卫生研究院网络， 该地区的研究。这些现有的关系和强大的基础设施现在可以用于艾滋病毒- 相关恶性肿瘤，这是马拉维和南非癌症负担的压倒性贡献者 即使是在广泛使用抗逆转录病毒疗法之后。USSACC专注于三种最常见的艾滋病毒- 相关癌症，卡波西肉瘤（KS），宫颈癌和淋巴瘤，并解决了NIH艾滋病毒/艾滋病 通过关注艾滋病毒相关的合并症，包括这些艾滋病定义的癌症，确定了研究的优先事项。 USSACC提出了艾滋病毒感染者这些癌症的筛查和预后创新 （PLWH），总体目标是改善PLWH的健康。 我们的联盟将由主要研究人员领导，他们具有高度互补的专业知识，使用团队科学 approach.为了支持联合体的目标，已经组建了一个多元化的调查团队， 临床，人口和基础科学，包括马拉维，南非和美国的科学领导人。 此外，一个高度优先事项是培训和支持美国和非洲的初级调查人员。的 联盟将加强所有合作伙伴之间现有的行政、运营和研究关系 机构和调查人员。外部咨询委员会和科学顾问将确保 联合会仍然高度响应马拉维和南非的社区需求，同时也解决 国际艾滋病毒相关癌症社区面临的紧迫研究问题。 该联盟的一个重点是发展马拉维和南非成为艾滋病毒方面的国际领导者， 相关的癌症研究。在本申请中概述的先前成功和伙伴关系的基础上， USSACC处于非常有利的地位，可以在马拉维促进广泛、协调的癌症控制工作， 南非，并推动撒哈拉以南非洲国家癌症研究所的总体科学议程，以减少艾滋病毒感染， 低收入和中等收入国家的相关癌症负担。